Dr. Schär closed FY 2025 with global sales of EUR 632 million. This represents an increase of 1.3% compared to 2024 (EUR 624 million). EUR 8.8 million was invested in improving the efficiency of production and logistics. A further EUR 28 million is planned for 2026 to expand production capacities in Italy, Spain, and Germany.

“We owe this result to our unwavering commitment across the entire value chain – from research and product development to production and sales,” the company highlights. “The international environment continues to be characterized by high complexity, highly volatile raw material prices, and a constantly changing geopolitical landscape,” commented Hannes Berger, CEO of Dr. Schär. “Against this backdrop, the performance in 2025 reflects the robustness of a long-term model that is capable of ensuring steady and responsible growth. The challenges we face reinforce our commitment to investing in innovation, quality, and a strong presence in our markets.”

The company reached the following milestones in 2025:

• France and Austria operations reach the 10-year mark in operation
• The Semper portfolio was transferred to Schär in Scandinavia
• A new office opened in Stockholm
• The transition to the exclusive use of cage-free eggs was completed, and the German sites in Dreihausen and Apolda switched to certified renewable electricity. Photovoltaic systems will be installed at the Klagenfurt (Austria) site later this year.

Schär is considered the market leader in the gluten-free segment. Its portfolio also includes the Flavis line – specializing in low-protein diets – and Kanso, a brand developed for therapeutic ketogenic diets.

Photo: Dr. Schär